
限制性治疗标准改善慢性淋巴细胞白血病预后预测:巴西注册研究的见解
巴西慢性淋巴细胞白血病(CLL)小组支持的限制性治疗启动方法,能够更准确地识别高风险患者,并避免低风险患者接受不必要的治疗,显示出比国际指南更好的预后分层。
Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.